Good time to highlight my impeccable flight etiquette:→ I have snacks (protein bars, water, edamame)→ Tech kit for emergency charges, cables, headphones→ I won't have to piss, but I will get up and stretch around hour 5. Just some calf raises and toe touches.→ I will neatly eat and throw away my in-flight meal (I'll also wake you for yours if requested)→ I only take up one seat→ I tip all flight attendants 20% of flight, as is commiserate of a US-based serviceBonus:If you want extra airline snacks I know ho ...

Core Viewpoint - Burcon NutraScience Corporation is set to showcase its innovative Chipotle Black Bean Protein Hummus at the IFT FIRST Annual Event & Expo, highlighting its advancements in plant-based protein technology [1][6]. Group 1: Product Innovation - The Chipotle Black Bean Protein Hummus is crafted using Burcon's proprietary triple blend of Peazazz®C pea protein, Puratein®C canola protein, and Solatein™ sunflower protein, resulting in a dip that is both flavorful and nutritious [6][8]. - Burcon's plant-based proteins boast over 90% purity, neutral flavor, and smooth mouthfeel, making them suitable for various food applications [6][9]. Group 2: Event Details - The IFT FIRST event will take place in Chicago from July 13-16, 2025, where Burcon will be located at booth S4066 [1][6]. - Attendees will have the opportunity to sample the Chipotle Black Bean Protein Hummus during a special tasting event on July 14 and 15, from 11:00 AM to 1:00 PM [7][9]. Group 3: Company Background - Burcon NutraScience is recognized as a global leader in high-performance plant-based proteins, with a strong commitment to sustainability and innovation in the food and beverage industry [11]. - The company holds an extensive patent portfolio covering novel proteins derived from various plant sources, positioning itself as a key player in the growing plant-based market [11].

Core Viewpoint - IGI Therapeutics and AbbVie have entered into an exclusive licensing agreement for ISB 2001, a novel trispecific T-cell engager targeting multiple myeloma, which is currently in Phase 1 clinical trials [1][2]. Company Overview - IGI Therapeutics is a clinical-stage biotechnology company focused on developing innovative biologics in oncology, utilizing its proprietary BEAT® technology platform to create first-in-class multispecific therapies [7]. - AbbVie is a global biopharmaceutical company dedicated to discovering and delivering innovative medicines across various therapeutic areas, including oncology [8]. Product Details - ISB 2001 is designed to target BCMA and CD38 on myeloma cells and CD3 on T cells, aiming to improve safety and efficacy compared to first-generation bispecific antibodies [3]. - The drug has shown a sustained overall response rate (ORR) of 79% and a complete/stringent complete response (CR/sCR) rate of 30% in a heavily pretreated patient population [3]. Licensing Agreement - Under the agreement, AbbVie will have exclusive rights to develop, manufacture, and commercialize ISB 2001 in North America, Europe, Japan, and Greater China [2]. - IGI will receive an upfront payment of $700 million and could earn up to $1.225 billion in milestone payments, along with tiered, double-digit royalties on net sales [2]. Regulatory Designations - ISB 2001 received Orphan Drug Designation from the U.S. FDA in July 2023 and Fast Track Designation for treating relapsed/refractory myeloma patients in May 2025 [4]. BEAT® Platform - The BEAT® platform enables the development of next-generation immune cell engagers with enhanced stability and function, addressing limitations of traditional bispecific antibody production [5]. - Key features include multispecific versatility, optimized engineering for precise modulation, and robust manufacturability [5].

ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM)NORTH CHICAGO, Ill. and NEW YORK, July 10, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), today announced an exclusive licensing agreement for IGI's lead investigational asset, ISB 2001, developed using IGI's proprietary BEAT® protein platform, for oncology and autoimmune diseases."Multispecifics ...

Core Insights - OraSure Technologies, Inc. has launched the HEMAcollect™ ● PROTEIN product aimed at enhancing proteomic research through improved sample collection and preservation [1][2] - The HEMAcollect™ ● PROTEIN is an evacuated blood collection tube designed to stabilize plasma proteins for up to seven days, addressing limitations of traditional blood collection methods [1][2] - The product is expected to provide operational and financial efficiencies for proteomic researchers, facilitating high-quality data generation [1] Product Features - The HEMAcollect™ ● PROTEIN BCT utilizes ProteoPrecision™ technology to minimize hemolysis and platelet activation, ensuring sample integrity [2] - It is compatible with various proteomic technologies, including mass spectrometry and immunoassays, making it versatile for different research applications [2] Company Overview - OraSure Technologies focuses on transforming healthcare through innovative diagnostic tests and sample management solutions, serving a wide range of customers including clinical laboratories and pharmaceutical companies [4] - DNA Genotek, a subsidiary of OraSure, specializes in developing products that optimize sample collection and performance for high-quality biological samples [5]

GREELEY, Colo., July 09, 2025 (GLOBE NEWSWIRE) -- Pilgrim’s Pride Corporation (NASDAQ: PPC) announced today that it will release its second quarter 2025 financial results after the U.S. market closes on Wednesday, July 30. The company’s executives will review the results on a conference call and webcast on Thursday, July 31, 2025, at 7:00 a.m. MT (9:00 a.m. ET). Prepared remarks regarding the company’s financial and operational results will be followed by a question and answer period with the Pilgrim’s exec ...

Industry Overview - The agriculture industry is undergoing a significant transformation driven by advanced technologies and innovations, addressing the urgent need for sustainable and efficient farming practices due to global population growth and climate change [2][3] - Agricultural technology (AgTech) and food innovation are pivotal in revolutionizing food production, enhancing productivity, and reducing environmental impact [2][3] AgTech Innovations - AgTech is reshaping food production, processing, and distribution through advancements in artificial intelligence (AI), biotechnology, and automation, leading to smarter and more sustainable agriculture [3] - Technologies such as precision farming, lab-grown meat, and plant-based alternatives are at the forefront of this transformation, enabling farmers to optimize operations and reduce resource waste [3][5] Protein Market Transformation - The global protein market is shifting towards healthier and more sustainable alternatives, including plant-based proteins and lab-grown meat, driven by health-conscious consumers [4] - Companies like Ingredion Incorporated are investing in plant-based ingredients to meet the rising global demand for sustainable protein solutions [4] Supply Chain Enhancements - Emerging technologies like blockchain and the Internet of Things (IoT) are improving food traceability and safety standards while minimizing waste in logistics and distribution [5] - Automation in food processing and packaging is enabling companies to deliver fresher products more efficiently and reduce operational costs [5] Investment Opportunities - Companies adopting advanced technologies are gaining a competitive edge, with top-performing stocks in AgTech and food innovation presenting compelling investment opportunities [6] - Industry leaders such as Beyond Meat, Hormel Foods, and Tyson Foods are leveraging AgTech to enhance growth and competitiveness [6] Beyond Meat Initiatives - Beyond Meat is focused on redefining protein production through innovative plant-based meats that replicate traditional animal products, addressing climate change and public health challenges [8] - The company is expanding its global footprint and investing in sustainable product development and supply chain transformation [11] Hormel Foods Strategies - Hormel Foods is utilizing digital technologies and AgTech solutions to enhance operational efficiency and food production standards, including a $1.7 million investment in regenerative agriculture [11][13] - The company is expanding its innovation pipeline with a focus on alternative protein development through partnerships, such as with The Better Meat Co. [12] Tyson Foods Transformation - Tyson Foods is investing in agricultural technology and food innovation to support sustainable protein production and digital transformation [14] - The company is enhancing operational efficiency through automation and logistics improvements, aiming for $200 million in annual savings by 2030 [16]

– John Houston, Ph.D., Chairperson, CEO and President at Arvinas, Announces Plans to Retire as CEO Upon Appointment of Successor – – Dr. Houston to Remain Chairperson of Arvinas Board of Directors – About Arvinas Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC protein degrader platform, Arvinas is pioneering the development of protein degradation therapies designed to h ...

Company Overview - BellRing Brands, Inc. (NYSE: BRBR) is a fast-growing consumer brands business focused on the convenient nutrition category, with brands such as Premier Protein and Dymatize [3] - The company aims to change lives with good energy and believes nutrition is essential for a healthy world, producing products with top nutritional profiles and flavors [3] - BellRing's products are distributed in over 90 countries across various channels including club, mass, food, eCommerce, specialty, drug, and convenience [3] Upcoming Financial Events - BellRing Brands will hold a conference call on August 5, 2025, at 9:00 a.m. EDT to discuss its financial results for the third quarter of fiscal year 2025 and provide an outlook for the fiscal year [1] - The financial results for the third quarter will be released after market close on August 4, 2025 [1] - The call will feature participation from Darcy H. Davenport, President and CEO, and Paul A. Rode, CFO [1]

China Healthcare | Asia Pacific Weekly Rx Express 2025.07.04 July 4, 2025 01:46 PM GMT Sino Biopharma obtained approval for recombinant human coagulation factor VIIa N01: The drug is indicated for the treatment of bleeding episodes in congenital hemophilia patients aged 12 and above, with factor VII or IX inhibitors >5 Bethesda units (BU). (Company filing, July 4, 2025) Hengrui obtained approval for an additional indication for JAK1 inhibitor (ivarmacitinib): Ivarmacitinib is China's first domestically-deve ...